Lundbeck launches Vyepti
Adults with migraine have a new intravenous preventive therapy.
Lundbeck is releasing Vyepti (eptinezumab-jjmr), the first and only intravenous treatment for migraine prevention. Vyepti can be obtained via select specialty distributors and specialty pharmacies.
“We are pleased to announce the availability of Vyepti for migraine prevention in the United States, along with a suite of online resources for patients and their healthcare providers, which we hope will be useful to learn more about this new treatment option,” said Peter Anastasiou, Lundbeck’s executive vice president, North America. “While we recognize and face the challenges of this global pandemic together, Lundbeck remains steadfast in our commitment to bring Vyepti to patients."
Lundbeck said it is responding to challenges posed by COVID-19, by adjusting its launch activities to largely center on delivering content virtually, digitally and socially, so patients and their healthcare providers are informed about this new treatment option.
“It is a new era in the treatment of migraine disease. We now better understand the pathways of migraine and have a variety of innovative medicines and devices that can prevent and treat migraine attacks, including Lundbeck’s new treatment. We thank the companies, scientists and patients that have contributed to the research that is making effective migraine management a real possibility for millions of Americans,” said Kevin Lenaburg, executive director for the Coalition for Headache and Migraine Patients. “I encourage everyone with migraine to talk with their healthcare provider about what option will work best for them.”